Skip to content

Efficacy of human atrial natriuretic peptide for the patients with severe sepsis; Impact on prevention against acute kidney injury

Efficacy of human atrial natriuretic peptide for the patients with severe sepsis; Impact on prevention against acute kidney injury - SANP

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000003821
Enrollment
60
Registered
2010-06-24
Start date
2010-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe sepsis

Interventions

The patients with severe sepsis are treated following Surviving Sepsis Campaign guidelines 2008. Patients are randomly assigned to receive hANP or distilled water (placebo) for continuous infusion.
severe hypotension, drug allergy, anaphylaxis, severe organ failure and so on due to hANP. Severe hypotension is defined as mean arterial pressure will be less than 65mmHg and simultaneously re-admini
Dopamine (mcg/kg/min) + Dobutamine (mcg/kg/min) + Noradrenaline (mcg/kg/min) * 100) The patients with severe sepsis are treated following Surviving Sepsis Campaign guidelines 2008. Distilled water
Dopamine (mcg/kg/min) + Dobutamine (mcg/kg/min) + Noradrenaline (mcg/kg/min) * 100)

Sponsors

Tosei General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The eligibility criteria for the study are age older 16 years and the presence of severe sepsis or septic shock. Patients, who have renal failure according to RIFLE category or are dependent on mechanical ventilation including non-invasive ventilation, are enrolled. All patients are needed to have written informed consent before enrolment in the study.

Exclusion criteria

Exclusion criteria: Patients are excluded (a)if they have already introduced maintenance HD before admission, (b)have got abdominal surgery for perforation of digestive tract, (c)have fallen in sepsis for more than 48 hours before the start of antibiotic therapy, (d)can't get out of septic shock within 72 hours after the start of antibiotic therapy, (e)have severe chronic heart failure as NYHA III or IV, (f)known pregnancy, (g)expected stay in the intensive care unit of less than 3 days, or (h)poor chance of survival.

Design outcomes

Primary

MeasureTime frame
30-day mortality

Secondary

MeasureTime frame
Renal function Introduction of maintenance haemodialysis (HD) Ventilator free days 90-day mortality

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026